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Progressive myopathy is a major clinical feature of patients with mitochondrial DNA (mtDNA) disease. There is
limited treatment available for these patients although exercise and other approaches to activate muscle stem
cells (satellite cells) havebeen proposed. The majorityofmtDNA defectsare heteroplasmic (a mixtureof mutated
and wild-type mtDNA present within the muscle) with high levels of mutated mtDNA and low levels of wild-type
mtDNA associated with more severe disease. The culture of satellite cell-derived myoblasts often reveals no evi-
dence of the original mtDNA mutation although it is not known if this is lost by selection or simply not present in
these cells. We have explored if the mtDNA mutation is present in the satellite cells in one of the commonest gen-
otypes associated with mitochondrial myopathies (patients with single, large-scale mtDNA deletions). Analysis
of satellite cells from eight patients showed that the level of mtDNA mutation in the satellite cells is the same as in
the mature muscle but is most often subsequently lost during culture. We show that there are two periods of se-
lection against the mutated form, one early on possibly during satellite cell activation and the other during the
rapid replication phase of myoblast culture. Our data suggest that the mutations are also lost during rapid
replication in vivo, implying that strategies to activate satellite cells remain a viable treatment for mitochondrial
myopathies in specific patient groups.
INTRODUCTION
Mitochondrial myopathies are an important group of muscle
conditionscausedbydefects inmitochondrial oxidativephosphor-
ylation. Patients often present with muscle weakness, although
fatigue and exercise intolerance are frequently a problem. In
some patients, the predominantly proximal myopathy is accom-
panied by severe involvement of the extraocular muscles leading
to chronic progressive external ophthalmoplegia (CPEO) (1),
while inothers it is part of amulti-systemdisorder.Themyopath-
ic symptoms are progressive and disabling in many patients.
Unfortunately, there is little in the way of specific treatment.
Primary mutations of mitochondrial DNA (mtDNA) are a
common cause of mitochondrial myopathy and may be either
point mutations or single, large-scale mtDNA deletions. MtDNA
is present in tissues in multiple copies and the mtDNA mutations
causing mitochondrial myopathies are frequently heteroplasmic,
with a mixture of mutated and wild-type forms (2–4). The vast
majorityofmtDNAmutations are functionally recessiveandabio-
chemical deficit is only observed when there are high levels of
mutated mtDNA and low levels of wild-type mtDNA (5,6). Het-
eroplasmic mtDNA defects classically give rise to the mosaic
pattern of cytochrome c oxidase (COX) normal, intermediate
and deficient muscle fibres (7–9).
Heteroplasmic mtDNA mutations may be maternally inher-
ited or occur sporadically. Inherited point mutations often have
a widespread tissue distribution and are rarely restricted to a
single tissue, although the levels may vary between these
tissues. Sporadic mtDNA mutations, either point mutations or
single, large-scale mtDNA deletions, are likely to be at much
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higher levels in post-mitotic tissues such as muscle when com-
pared with replicating tissue (2,10,11). Even when single,
large-scale mtDNA deletions are found in replicating tissues
such as blood, the mutations tend to be lost rapidly (12,13), im-
plying a selection against cells with a biochemical deficiency on
account of high levels of mutation.
The treatment of patients with mitochondrial myopathies
remains extremely challenging. Several groups have investi-
gated patients with sporadically occurring mtDNA mutations
to determine whether it might be possible to employ a novel ap-
proach to therapy by stimulating the growth ofmuscle stem cells
(satellite cells). Previous observations have demonstrated that
the disease-causing mtDNA defect is absent in cultured myo-
blasts of patientswith sporadically occurringmtDNAmutations,
suggesting that themtDNAdefect is not present, or is very low in
satellite cells (14–16). Satellite cells lie on the muscle fibre
underneath the basal lamina and share a common dermomyo-
tome embryological origin with developing muscle progenitor
cells (17). They are responsible for muscle growth, repair and
hypertrophy. In response to activation, they form proliferating
myoblasts which differentiate into myotubes and fuse into the
muscle fibre to repair it or contribute to hypertrophy (18). Satel-
lite cells can be identified by their expression of transcription
factors (e.g. Pax 7) and adhesion molecules [e.g. neural cell ad-
hesion molecule (NCAM) and M-cadherin] (19). There has,
however, been considerable debate regarding what constitutes
‘the true muscle satellite cell’, with evidence suggesting that
the satellite cell population is heterogeneous basedonmarker ex-
pression (20). In addition, themajority of research involving sat-
ellite cells occurs in rodents and themarkers have been shown to
differ from those in humans (21).
A number of studies have attempted to shift the levels of
wild-type and mutated mtDNA in the muscles of affected
patients. Two early studies, which involved either injecting
myotoxic bupivacaine hydrochloride or trauma induced by
re-biopsying to damage muscle, were successful in favourably
changing themtDNAbalanceandcharacteristics of regenerating
muscle fibres (22,23). While these approaches showed promise,
they were not practical and a less severe method of inducing
satellite cell activation was required. More recently, resistance
exercise training has been evaluated as a method of damaging
muscle fibres and inducing satellite cell activation. These
experiments have demonstrated marked improvements in mito-
chondrial activity in muscle as evidenced by a decrease in the
proportion of COX-deficient fibres (fibres with low mitochon-
drial activity) but with inconsistent outcomes on the mtDNA
genotype (24,25).
Single, large-scale mtDNA deletions are common causes of
mitochondrial myopathies with patients presenting with either
a proximalmyopathywith associated CPEO, orwith amore sys-
temic illness such asKearns–Sayre syndrome.Toestablish if ac-
tivating satellite cells is a viable treatment in these patients, we
investigated the differences in deletion load betweenmuscle sat-
ellite cells and mature muscle in eight patients. Both satellite
cells and muscle have the same embryological origin and,
even though experiments in vitro and in vivo have suggested
that myoblasts have low or absent levels of mutation, under-
standing themechanismof this remarkable difference compared
with the mature muscle might facilitate different therapeutic
strategies to help patients with mitochondrial myopathies.
RESULTS
Patients and samples
Samples were collected from a total of eight patients (Table 1).
For some patients (1, 2, 3, 4, 5 and 7), repeat muscle biopsy
samples were available, whereas for others (6 and 8) tissue from
only a single biopsy was taken.
Satellite cells were obtained frommuscle biopsies with Fluor-
escently Activated Cell Sorting (FACS) using an antibody
(CD56) which recognizes the adhesion molecule NCAM.
Between 1251 and 36 136 CD56+ cells were isolated per
biopsy, constituting 3–7% of the total cell number in the
sample. In addition to collecting a homogenate sample of
CD56+ cells, for Patient 7 it was possible to FACS sort single
CD56+ cells into wells of a 96-well plate for further analysis.
We had the opportunity to establish myoblast cultures from
seven of the seventeen biopsies performed; in the other cases
not enough tissue was available for cell extraction.When cultur-
ing primary myoblasts, fibroblast contamination is a common
finding. To determine the myoblast purity of our cells, immuno-
fluorescent detection of the myogenic marker desmin was per-
formed. This revealed the percentage of myoblasts to be
84.5%+ 13.1 (SD) (Supplementary Material, Table S1).
Quantification of single, large-scale mtDNA deletions
in CD561 cells
It was demonstrated using quantitative PCR (qPCR) methods,
(MTND1/MTND4 TaqManw and SYBRw Green) (Fig. 1), that
all eight patients enrolled in the study harboured single mtDNA
deletions in their CD56+ cells at levels very similar to those of
mature muscle (Table 2). The average heteroplasmy level in
CD56+ cells was 44.8+23.5% (SD) (n ¼ 17) and in the muscle
homogenate it was 48.1+17.5% (n ¼ 8). A paired t-test revealed
that there was no significant difference between the mtDNA dele-
tion levels in CD56+ cells and in mature muscle homogenate
samples (P ¼ 0.48).
To confirm this finding, we investigated CD56+ cells from
two patients (1 and 6) using long-range PCR. In both subjects,
this showed a single, large-scalemtDNAdeletion of appropriate
size (Table 1), providing further confirmation that this mtDNA
mutation was present in the satellite cells (Fig. 2).
MtDNA deletions in myoblasts
Sufficient muscle tissue was available from five of the eight
patients (Patients 2, 3, 4, 5 and 6) to establish primary myoblast
cultures; from Patients 2 and 3 it was possible to establish myo-
blast cell cultures from two separate biopsies, giving a total of
seven myoblast cultures that were investigated. Myoblasts
were subcultured up to passage 6 or 7 before being differentiated
into myotubes; however, this was not possible in all cases as
some of the cells were growing extremely slowly. These cells
were therefore differentiated at earlier passages.A small fraction
of cells were retained after each passage to investigate the
levels of patient-specific, single, large-scale mtDNA deletions
(Table 3). Single, large-scale mtDNA deletions were not
present in myoblasts from Patients 4, 5 and 6. However,
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myoblasts grown from two separate muscle biopsies from
Patient 3 behaved very differently. The myoblasts grown from
one biopsy contained no detectable levels of single, large-scale
mtDNA deletion after the first passage, but myoblasts obtained
from a subsequent biopsy harboured the mtDNA deletion. The
myoblasts obtained from both muscle biopsies of Patient 2 con-
tained a single, large-scale mtDNA deletion.
Single, large-scale mtDNA deletions were therefore detected
in three out of the seven myoblast cell cultures investigated. In
two out of the three myoblast cell cultures that originally main-
tained the genetic defect, there was a gradual decline as the cells
proliferated and differentiated into myotubes (Table 3). To de-
termine whether the process of differentiation resulted in myo-
genic cells losing their mtDNA mutation, myoblasts from
Patients 2 and 3 were differentiated into myotubes at an earlier
passage (Table 4). However, this had no effect on their hetero-
plasmy level, suggesting it was the process of myoblast prolifer-
ation and not differentiation that caused the reduction inmtDNA
deletion levels.
In view of the persistence of a single, large-scale mtDNA de-
letion in myoblasts from two of our patients we wanted to
exclude the possibility of an mtDNA duplication, which might
explain the persistence of the mutation (26). A Southern blot,
using BamHI and SnaBI (Supplementary Material, Fig. S1A)
to digest mtDNA obtained from the myoblasts of Patient 2,
showed no evidence of a duplication (Supplementary Material,
Fig. S1B). In addition, since in patients with duplications the re-
arrangement often persists in replicating tissues (26), we
checked for the presence of the single, large-scale mtDNA dele-
tion in blood from Patients 2 and 3, and urine from Patient 2 and
could not detect it (data not shown).
Single cell investigations
It was decided to investigate whether the levels of single,
large-scalemtDNAdeletionswere a result of all cells harbouring
the same amount of mutation, or if satellite cells and myoblasts
are a heterogeneous population based on single, large-scale
Table 1. Clinical and molecular genetic characteristics of our patient cohort
Patient Sex Age Age at onset of disease Symptoms MtDNA deletion size (bp) MtDNA deletion breakpoints
1 F 58 37 CPEO, EI, fatigue 3693 nt.9756-nt.13449
2 M 46 28 CPEO, EI, fatigue, GI problems 4978 nt.8469-nt.13447
3 M 39 16 CPEO, EI, fatigue, GI problems 4113 nt.11262-nt.15375
4 M 59 10 CPEO, EI, fatigue, ptosis 4978 nt.8469-nt.13447
5 M 45 29 CPEO, EI, fatigue, ptosis 7595 nt.7845-nt.15440
6 M 35 33 CPEO, EI, fatigue, GI problems 8039 nt.7637-nt.15676
7 M 31 16 CPEO, EI, fatigue, SVT 4978 nt.8469-nt.13447
8 F 34 9 CPEO, ptosis, mild dysphagia 5340 nt.6714-nt.12054
All patients displayed symptoms of myopathy, with CPEO and either ptosis or exercise intolerance (EI). All patients harboured a sporadically occurring single,
large-scale mtDNA deletion, with precise mapping of the mtDNA deletion breakpoint showing that three patients (Patients 2, 4 and 7) had the 4977 bp common
mtDNA deletion.
SVT, supraventricular tachycardia; GI, gastrointestinal tract.
Figure 1. Deletion-specific SYBRw Green qPCR. (A) Reaction designed to amplify only wild-type mtDNA, with primers chosen to anneal to regions within the
breakpoints of the deletion. These primers will therefore not allow amplification of mtDNA containing a deletion. (B) The reaction designed to amplify mtDNA
harbouring a deletion used primers that annealed to either side of the breakpoint. Owing to the extension time of the qPCR only mtDNA with a deletion would
have an amplicon short enough to be amplified.
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mtDNA deletion levels. Single CD56+ cells from Patient 7 and
single myoblasts from two biopsies of Patient 2 were FACS
sorted into a 96-well plate. Both CD56+ cells and myoblasts
were shown to be a heterogeneous population based on
mtDNA deletion levels, with levels ranging from very high to
very low (Fig. 3). FACS analysis can only be performed on
live cells and, due to the timing of muscle biopsies, it was only
possible to investigate single satellite cells and single myoblasts
from these two patients.
MtDNA copy number
The copy number of mtDNA was determined using qPCR to
compare a nuclear marker, 18S rRNA, with the MTND1
region. In all the patients, the mtDNA copy number of CD56+
cellswas low.While therewas somefluctuation, therewas an in-
crease in the mtDNA copy number after satellite cell activation
(Fig. 4), which increased further during myoblast proliferation.
DISCUSSION
This research aimed to determine the reason for the loss of
sporadically occurring mtDNA mutations from regenerating
muscle cells in patients with mitochondrial myopathies
(22–24). The main findings were that: (i) mtDNA mutations
were present in satellite cells of all eight patients with myopathy
caused by a sporadically occurring, single, large-scale mtDNA
deletion at levels comparable with that observed in muscle; (ii)
mtDNA deletions persisted in the myoblasts of only some
patients; (iii) mtDNA deletions appear to be lost at two stages;
firstly very early on during the initial myoblast proliferation
phase or during satellite cell activation and secondly during
later myoblast proliferation; (iv) muscle regeneration with
incorporation of satellite cells remains a viable therapy in
patients with sporadically occurring conditions, although the
mechanisms around the process are somewhat different from
that originally hypothesized. We believe this work not only
has implications for the treatment of mitochondrial disease,
but also adds toourknowledge regardinghowmtDNAmutations
segregate during development and are lost from certain cellular
populations.
Satellite cells and skeletal muscle share a common embryo-
logical origin: they are both derived from the dermomyotome
region of the somites that have budded off from the mesoderm
during development (17). Our results demonstrating no signifi-
cant difference in mtDNA heteroplasmy levels between
muscle satellite cells and mature skeletal muscle are in some
ways not surprising. While there is an eventual demarcation
between muscle stem cells that form skeletal muscle and those
that will form satellite cells, it would appear that the mutation
has occurred and segregated to these cells before this separation.
This would agree with previous studies showing that single,
large-scale mtDNA deletions are present in the early embryo,
as demonstrated by the same mtDNA deletion being identified
in bothmembers of a pair of identical twins (27). It is interesting
to note that our study and others (14,15,22,24) have shown that
sporadically occurringmtDNAmutations can be lost from repli-
cating myoblasts during the process of muscle regeneration;
however, the mutation has not been lost from replicatingT
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myoblasts during embryological development. At this stage, we
can only speculate on this; it is possible that thematuremuscle is
a more hostile environment than embryologically developing
muscle and therefore the selection pressures are stronger, or
maybe during development muscle precursor cells do not
divide as many times as required to select against the mutation.
When individual satellite cells from Patient 7 were inves-
tigated, they showed variable levels of mutated mtDNA,
ranging from very high to very low. This is interesting because
it suggests that there is very little, if any, selection for or
against single, large-scale mtDNA deletions in the satellite
cells. Satellite cells are largely quiescent and contain very few
mitochondria. The extreme variation in mutation load suggests
either an mtDNA genetic bottleneck during embryogenesis
during the formation of satellite cells, or random drift of
mutation load with time.
Given the previous findings of little or nomtDNAmutation in
the myoblasts of patients with sporadically occurring mitochon-
drial diseases, itwas expected that themtDNAmutationwouldbe
absent from the culturedmyoblasts of our patients. However, we
observed remarkable differences not only between patients, but
in one case between biopsies from the samepatient, in the hetero-
plasmy levels of cultured myoblasts. In the majority of cultures,
the mtDNA mutation was rapidly lost. In two of the three cases
where the single, large-scale mtDNA deletion was detected in
the myoblasts, the mutation levels decreased as the cells
headed towards differentiation. Single myoblasts from both of
the biopsies from Patient 2 were heteroplasmic for single,
large-scale mtDNA deletions. This has been reported in a previ-
ous investigation that demonstrated the heteroplasmic status of
clonal myoblasts from patients with single, large-scale mtDNA
deletions and Kearns–Sayre syndrome (16).
Figure 2.Long-range PCR gels demonstrating single mtDNAdeletions in CD56+ cells after two rounds of amplification. (A) CD56+ cells from Patient 1 were amp-
lified with primers (SupplementaryMaterial, Table S3) to generate a 7965 bpmtDNA fragment. PCR products were then diluted 1:50 (lane 1) and 1:100 (lane 2) and
amplified a second timewith primers whichwould generate a 7063 bp fragment in a control DNA sample (lane 3). Bands of 3500 bp can be observed in the patient
samples (lanes1 and2), confirming adeletionof3500 bpwhichcorresponds to that determinedbybreakpoint sequencing (Table1). (B)Muscle homogenate (lane1)
and CD56+ cells (lane 2) from Patient 6 were amplified with primers to generate a 10 774 bp mtDNA amplimer. Products were diluted and re-amplified using PCR
primers togenerate a 8995 bpmtDNAfragment.Bandscanbe seencorresponding to an1000 bpamplicon,whichcorresponds to themtDNAdeletionmapped in this
patient that is 8039 bp (Table 1).
Table 3. MtDNA heteroplasmy levels in myoblasts and myotubes
Patient 2 3 4 5 6
Biopsy First Second Second Third Second First First
Myoblasts Passage 1 ND ND 0.75%+0.1 ND 0% 0% ND
Myoblasts Passage 2 ND ND 0% 61%+14 0% 0% ND
Myoblasts Passage 3 ND 78.8%+0.9 0% 68%+9 0% 0% 0%
Myoblasts Passage 4 35%+1.6 79.5%1.0 0% 68%+7 ND 0% 0%
Myoblasts Passage 5 33%+1.0 81.25%+0.8 0% 56.9%+0.006 ND 0% 0%
Myoblasts Passage 6 34.75%+0.4 79%+1.4 ND 43%+12 ND 0% 0%
Myoblasts Passage 7 34%+4.0 ND ND 23.5%+2.8 ND 0% 0%
Myotubes 22.25%+0.8 79.7%+0.004 0% 0% 0% 0% 0%
QPCR assays were used to quantify levels of mtDNA containing a deletion in myoblasts at different passages, and myotubes. Myoblasts from three of the seven cell
cultures harboured singlemtDNAdeletions after thefirst passage, andwhen these cellswere differentiated intomyotubes, the deletionwas lost completely fromoneof
the cell cultures and reduced in another. It was not always possible to grow the cells up to passage 7 before differentiating them into myotubes due to slow growth;
additionally some cell cultures were only obtained from the Biobanking facility after a number of passages.
Values are means+SE.
ND, analysis not done.
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Thedifferences in the behaviour of themyoblasts fromPatient
2 are intriguing,with one cell culture showing increased levels of
mtDNAmutationwhen comparedwithmaturemuscle and satel-
lite cells, and one with lower levels. The age and heteroplasmy
levels in this patient were no different from other patients, and
the deletion was the so-called ‘common deletion’ (4), which
was also present in Patients 4 and 7 in our study. Why this
patient behaves sodifferently is unknownbut highlights that seg-
regation of mtDNA mutations between cells is not straightfor-
ward and likely to represent both the selection pressures and
nuclear genome effects. Interestingly, this patient had no evi-
dence of the single, large-scale mtDNA deletion in blood or
urine (data not shown) and thus selection had occurred in other
tissues.
When culturing myoblast primary cells, fibroblast contamin-
ation is a common occurrence, andwhilewe demonstrated a rea-
sonably high level of myoblast purity, we still had some
fibroblast contamination. Fibroblasts have previously been
shown to be free of mtDNAmutations in patients with sporadic-
ally occurring mitochondrial diseases (14,15); this may have
resulted in a lower observed mtDNA deletion load in the myo-
blasts of our patients. While satellite cells were originally
defined according to their anatomical location (28), it is now
clear they are a heterogeneous population based on their expres-
sion of different markers. Most previous work in satellite cell
biology has been performed on mice, and there is therefore a
lack of specific markers and thus commercially available anti-
bodies for human satellite cells (21). This study used CD56
(NCAM) to isolate satellite cells because it is amarker that iden-
tifiesmyogenic cells in humans; in addition, there is a good, com-
mercially available, directly conjugated antibody for this
marker. Reports have demonstrated the presence of NCAM in
various components of the blood (29), but these cells are unlikely
to contaminate in view of thewashing prior to FACS sorting and
also the fact that in blood samples sporadically occurring, single,
large-scale mtDNA deletions are often absent.
It would appear that regenerating muscle cells are subjected to
two periods of selection, with the first phase occurring very early
onbeforemyoblastswereassessedformutation levels. It isdifficult
to determine how selection occurred at this stage as it is possible
that the mutations might have been lost at the point of satellite
cell activation or that the mutation might have been lost from the
myoblasts themselves during the early stages of proliferation
before we were able to assess mutation levels. Our data suggest a
very small amount of mtDNA is present in satellite cells and thus
during replication into myoblasts selection pressure may be
extreme. If this were the case, it would explain why the single,
large-scale mtDNA deletion is lost so early in the majority of
patient’s myoblasts. Alternatively or complementary to this, an
asymmetric division of the satellite cell after activation (30)
couldresult inonecell acquiringmoreor lessof thedisease-causing
mutation. Depending on which cell proceeds to form myoblasts
and which returns to repopulate the stem cell pool, the mutation
may be maintained or lost from the regenerating muscle cells.
The second selection point was a more gradual selection against
myoblasts with high levels of mtDNA deletion, whereby cells
with high levels of mutation were unable to proliferate as well.
An approach currently being investigated to help patients suf-
fering from mitochondrial myopathy caused by sporadically
Table 4. The effect onmtDNAheteroplasmy levels of differentiatingmyoblasts
into myotubes
Patient Biopsy Myoblasts
Passage 4
(%)
Myoblasts
Passage 5
(%)
Myotubes
Passage 5
(%)
Myoblasts
Passage 6
(%)
2 First 38 32 43 35
Second 79 81 87 79
3 Third 75 57 51 31
Myoblasts fromPatients 2 and 3, those thatmaintainedmtDNAdeletion levels in
their replicating myoblasts, were differentiated into myotubes at passage 5. The
mtDNA deletion levels in the myotubes were similar to those observed both
before differentiation and in the myoblasts of a subsequent passage that did not
undergo differentiation. This experiment was only performed on a single
occasion.
Figure3.MtDNAheteroplasmy levels in single satellite cells (CD56+) andmyo-
blasts. Single satellite cells were obtained from the second muscle biopsy of
Patient 7 by FACS sorting, and myoblasts were obtained from two biopsies
from Patient 2. Because of it’s sensitivity to low quantities of DNA, samples
were investigated using the commondeletionSYBRwGreen qPCR (Supplemen-
tary Material, Table S2). Both satellite cells and myoblasts were heterogeneous
based on mtDNA deletion levels. Lines indicate the mean heteroplasmy level of
the single cells, while open squares show the heteroplasmy levels determined for
the homogenate sample using the MTND1/MTND4 TaqManw qPCR.
Figure 4.RelativemtDNAcopy number inCD56+ cells and culturedmyoblasts.
Satellite cells contained low amounts ofmtDNA.Therewas a gradual increase in
the mtDNA copy number following activation, proliferation and conversion to
myotubes. Values are means+SE (n ¼ 7).
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occurring mtDNAmutations is resistance training. The purpose
of resistance training is 2-fold, to increasemuscle strength and to
incorporate cells harbouring lower or no mutated mtDNA (31).
The ‘proof of principle’ of gene shifting has already been estab-
lished (22–24). This current research suggests that the mechan-
ismof actionmay be different from that originally hypothesized.
Rather than the sporadically occurring mutation being absent
from satellite cells, it is present, but subsequently lost over two
selection points. This would suggest that resistance exercise
training still remains a viable therapy for themajority of patients
with sporadically occurring mtDNA mutations. However, it is
important to note that selection pressures in a cell culture envir-
onment differ from thematuremuscle in vivo and thus the behav-
iour of proliferative muscle cells may vary.While one myoblast
culture appeared to have entered into a steady-state regarding
mutation levels, the two cultures that decreased single mtDNA
deletion levels required a number of passages for this to occur.
Our primary cell cultures were propagated for around seven pas-
sages.While our two cell cultures that reduced inmtDNAmuta-
tion load did so over these seven passages, it is possible that in
vivo they may not have as many divisions in which selection
can occur. This highlights the need for further research in these
patient groups along the lines of that previously performed
(14,22,24,25) and with primary human myoblast cultures to
better characterize the regenerative response to satellite cell ac-
tivation, and reveal if there are anypatient characteristics that de-
termine whether patients maintain, lose or even increase the
mutation in their regenerating muscle cells.
In conclusion, we have shown that mtDNA mutations
are present in the muscle satellite cells of patients with mito-
chondrial myopathies due to sporadically occurring, single,
large-scale mtDNA deletions. In the majority of the patients,
thedeletion is lost during the transition fromsatellite cell tomyo-
blast. For those mutations found in the myoblasts, there is often
gradual loss of the mtDNA deletion with subsequent passages.
Thus, activation of satellite cells remains a viable option for
patients with sporadically occurring conditions; however, the
mechanisms behind the process are different from that originally
hypothesized.
MATERIALS AND METHODS
Subjects and samples
Ethical approval for this study was obtained from the Newcastle
and North Tyneside Local Research Ethics Committees and all
investigations were performed after informed consent was
obtained.
Muscle biopsies (vastus lateralis) were obtained from eight
patients [two females aged 46+ 17 (SD) years; six males aged
42.5+ 9.9 years] harbouring a sporadically occurring, single,
large-scale mtDNA deletion. All the patients presented with
CPEO and the majority had exercise intolerance and fatigue
(Table 1).
Isolation of satellite cells
Muscle sampleswere stored in solutionA(30 mMHEPES,130 mM
NaCl, 3 mMKCL, 11 mMGlucose, Phenol Red), until the isolation
of satellite cells could be performed. Muscle samples were
dissociated using a Medimachine (BD Biosciences) according to
the manufacturer’s instructions. Approximately 25 mg of muscle
and 500 ml of phosphate buffered saline was placed in a Medicon
(BD Biosciences) and put into the Medimachine for 20 s. The
blade inside the Medicon dissociated the sample and allowed the
cells to pass through a sieve into a collection chamber, thus separ-
ating them from the connective tissue. The cells were filtered
through a 30 mm filter (CellTricsw, Partec) and then counted
using a Beckman Coulter Cell Viability Analyser.
Phycoerythin (PE) labelled Mouse Anti-Human CD56 IgG1
(BD PharmingenTM) (NCAM) was incubated with the sample
(10 ml per million cells) for 30 min in the dark. The sample was
then washed using a BD LyseWash Assistant (BD Biosciences).
CD56 positive (CD56+) cells were isolated from the sample
using FACS on a FACSAria machine (BD Biosciences). The
sample was excited at 488 nm and the fluorescence registered
at 585 nm. The sample was collected in either a microcentrifuge
tube or in 96-well plates and then centrifuged at 166g for 5 min.
The supernatant was discarded and the cells stored at 2208C
until required.
Cell culture
Myoblast cell cultures were established by the MRC Centre for
Neuromuscular Diseases Biobank Newcastle, according to
established protocols (32). Muscle samples were stored in solu-
tion A and cultures established within 3 days. Myoblasts were
cultured in Skeletal Muscle Growth Medium (PromoCell) sup-
plemented with 10% foetal calf serum, 1.5% L-glutamine and
300 ml of gentamicin. Differentiation of myoblasts to myotubes
was performed by changing to a low serum medium (98%
DMEM and 2% horse serum) for 7 days. Differentiation was
determined to be successful if cells were visible containing
two or more nuclei. Harvesting and passaging of cells was
carried out by detaching the cells with trypsin and centrifuging
at 166g for 5 min; the supernatant was discarded, leaving a cell
pellet which was either frozen at 2208C or re-plated.
Desmin labelling
Todeterminemyoblast purity, cellsweregrownon cover slips and
labelled with monoclonal mouse anti-human desmin (DAKO).
Alexa Fluorw 2488 goat anti-mouse secondary antibody was
applied and the cells mounted with VECTASHIELDwMounting
MediumwithDAPI.CountswereperformedonanAxiovert200M
(Zeis), usingAxioVisionRelease4.6.3 software (Zeiss)withmyo-
blast purity being determined by the number of desmin+ DAPI+
cells compared with the number of Desmin2 DAPI+ cells.
DNA extraction
DNA was extracted from homogenate samples of CD56+cells,
myoblasts and myotubes using a Qiagen DNeasy Blood and
Tissue Kit according to the manufacturer’s instructions. DNA
was eluted in 40 ml of dH2O and stored at2208C until required.
Single cell DNA extraction was performed using lysis medium
consisting of 50 ml of 500 nM Tris–HCL, 250 ml of 1% Tween
20, 190 ml of dH2O and 5 ml of proteinase K (Invitrogen), of
which 15 ml was added to each cell. The cells were then
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incubated at 558C for 2 h and 958C for 10 min, and stored at 48C
until required (9).
MtDNA investigations
Taqmanw QPCR assay
To detect and quantify single, large-scale mtDNA deletions, the
MTND1/MTND4 qPCR multiplex TaqManw assay was used
(33,34). This method uses primers and fluorescent probes to
bind to the MTND1 (Forward nt.3485-nt.3504, Reverse
nt.3532-nt.3553, Probe nt.3506-nt.3529) and MTND4 (Forward
nt. 12087-nt.12109, Reverse nt.12140-nt.12170, Probe nt.12111-
nt.12138) regions of the mtDNA. All of the patients in this study
had the MTND4 region at least partly removed by their mtDNA
deletion, while the MTND1 sequence was spared in all cases.
The proportion of mtDNA harbouring a deletion was determined
by the established DCT method (34). Samples were run in tripli-
cate on an ABI Step One Plus Real Time PCR System (Applied
Biosystems), along with control samples of mtDNA with known
heteroplasmy levels.
Relative mtDNA copy number was determined by comparing
the nuclearmarker 18 s rRNA to the preservedMTND1 region in
a TaqManw assay. Primers and probes were used to amplify the
MTND1 (as above) and the 18s rRNA sequence (Forward
5′-GCC GCT AGA GGT GAA ATT CTT G-3′, Reverse
5′-CAT TCT TGG CAA ATG CTT TCG-3′, probe 5′-CCG
GCGCAAGACGGACCAGA-3′). Reactions were performed
in a 25 ml volume, consisting of 12.5 ml of TaqManw Universal
MasterMix, 0.75 ml of MTND1 forward and reverse primer
(10 mm), 0.5 ml of probe (5 mm), and 7.5 ml of dH2O and 1 ml
of sample DNA. The 18s rRNA master mix was identical to
MTND1 except with 0.13 ml of forward primer (10 mM) and
10.12 ml of dH2O. The two reactions were set up in parallel,
with each patient’s CD56+ cells, myoblasts and myotubes being
run together; blood and muscle DNA were included as controls.
The reaction conditions were 2 min at 508C, 10 min at 958C,
40 cycles of 15 s at 958C and 60 s at 608C. The MtDNA copy
number was calculated using the equation R ¼ 22DCt (34).
SYBRw green QPCR assays
Using primers specific to mtDNA breakpoint sequences, it is
possible to design quantitative real-time PCR assays specific
for an individual’s single, large-scale mtDNA deletion. These
specific assays have been able to accurately quantify very low
mtDNA deletion levels (27), using very small amounts of
DNA. This assay was therefore used to assess the level of
mtDNA heteroplasmy in a patient with low levels of mtDNA
deletion (Patient 5) and to confirm the absence or to quantify
low levels in the satellite cells and myoblasts of other patients.
Patient 5 had previously been shown to harbour low levels of a
single mtDNA deletion (9%) in his muscle based on Southern
blotting (Rare Mitochondrial Disorders of Adults and Children
Diagnostic Service, Newcastle upon Tyne). This is below the
sensitivity level of the MTND1/MTND4 TaqManw qPCR assay
(34). In addition, Patients 3, 4 and 6 were initially shown, using
theMTND1/MTND4TaqManwqPCRtohaveat leastonemyoblast
cell culturewithmtDNAdeletion levels below the sensitivity of this
assay.Afurther twoSYBRwGreenassayswere thereforedeveloped
(Supplementary Material, Table S2) and one assay re-optimized
(27) to determine the exact amount of delete mtDNA, if any, in
these cells.
Primers were designed using the Primer3 software (v.0.4.0)
(35) to amplify either wild-type or mutant (deleted) mtDNA.
The wild-type primers were designed to only amplify wild-type
mtDNAas the reverseprimerbinding sitewaswithin themtDNA
breakpoints of the deletion (Fig. 1A).Owing to the qPCR reaction
conditions the delete mtDNA primers would only amplify DNA
fragments if an mtDNA deletion of several Kb was present
(Fig. 1B). A standard curve for each assay was constructed
using wild-type mtDNA and delete mtDNA from the patient
with a known heteroplasmy level. The DCT for delete and wild-
type mtDNA was calculated for the samples and compared with
the standard curve to determine the exact heteroplasmy level.
Reactionswere performed on anABI StepOne Plus Real Time
PCR System (Applied Biosystems) using PlatinumwSYBRw-
Green qPCR SuperMix-UDG (Invitrogen) in a 25 ml volume,
with 1 ml of sample DNA. The cycling conditions were 958C
for 10 min, followed by 40 cycles of 958C for 15 s, and then the
relevant annealing temperature for 1 min (SupplementaryMater-
ial, Table S2); this was followed by a melt curve analysis to
confirm the specificity of the amplified product. Fluorescence
levels were acquired at the end of each cycle.
Long-range PCR
Long-range PCRwas performed onCD56+ cells fromPatients 1
and 6 using two rounds of amplification (36). The first round of
amplification for Patient 1 used primers (Supplementary Mater-
ial, Table S3) to generate a 7965 bp mtDNA fragment and for
Patient 6 the primers generated a 10 774 bp product. Products
were diluted in dH2O and amplified a second time. Patient 1
had primers designed to give a final 7063 bp product and
Patient 6 had primers to give a final fragment of 8995 bp. Amp-
lified products were separated on 0.7% agarose gels.
Southern blot
Rearrangements of mtDNA were screened for mtDNA duplica-
tions in total DNA extracted from myoblasts of Patient 2 using a
Southern blot, employing the enzymes BamHI and SnaBI, with
the SnaBI cutting within the deletion breakpoints and enabling
detection of any duplicated molecules. Products were probed
with a PCR-generated probe that hybridized against the non-
coding control region (37).
Statistical analysis
Data were analysed usingGraphPad Prism andMicrosoft Excel.
Anderson-Darling tests were used to test for normality and
means were compared with two sample t-tests.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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